Posted on 07/22/2024 9:11:05 PM PDT by ConservativeMind
New research shows combined use of sodium glucose co-transporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP1-RAs) is likely to offer additional protection against heart and kidney disease in patients with diabetes.
SGLT2is, also called gliflozins, are a class of drug that lower blood glucose by increasing its excretion in the urine, while GLP-1RAs, such as Ozempic, work by enhancing insulin release and sensitivity. Both classes of medicine have each been shown to improve cardiovascular outcomes. Although small, relatively short-term trials have suggested using these medicines together improves blood glucose control, their combined effects on heart disease and kidney failure are less clear.
Researchers involved in the SGLT2 Inhibitor Meta-analysis Cardio-Renal Trialists' Consortium (SMART-C) pooled data across 12 large-scale, placebo-controlled trials of SGLT2is involving 73,238 patients with diabetes, 3,065 of whom were already receiving GLP1-RAs. The meta-analysis showed that the benefits of SGLT2is were observed independent of GLP1-RA use.
SGLT2is reduced the risk of major adverse cardiovascular events (myocardial infarction, stroke, or cardiovascular death) by 11% and hospitalization for heart failure or cardiovascular death by 23% versus placebo, even when added to GLP1-RAs.
SGLT2is also reduced the risk of chronic kidney disease progression by 33% when added to GLP1-RAs and slowed the annual loss of kidney function by almost 60% when added to GLP-1RAs. No new safety concerns were identified when SGLT2is and GLP-1RAs were used in combination.
Neuen added that both classes of medicines work independently of each other, "SGLT2 inhibitors have clear protective effects against heart failure and chronic kidney disease, while GLP-1 receptor agonists can reduce the risk of heart attack, stroke, and also kidney disease—as recently demonstrated in the landmark FLOW trial.
"Our findings support using this combination to further improve outcomes in patients with type 2 diabetes who meet guideline recommendations for both therapies."
(Excerpt) Read more at medicalxpress.com ...
Major quotes:
“SGLT2is reduced the risk of major adverse cardiovascular events (myocardial infarction, stroke, or cardiovascular death) by 11% and hospitalization for heart failure or cardiovascular death by 23% versus placebo, even when added to GLP1-RAs.”
“SGLT2is also reduced the risk of chronic kidney disease progression by 33% when added to GLP1-RAs and slowed the annual loss of kidney function by almost 60% when added to GLP-1RAs. No new safety concerns were identified when SGLT2is and GLP-1RAs were used in combination.”
Taking both types of drugs provides big benefits.
I will suggest this tells me just how important reducing all calories and greatly adjusting how carbs are used, really is. The drugs appear to do amazing things together, but diet and exercise might come close to parts of these results, too.
But, but, but,....
Off label use of a drug?? We have been advised ad nauseum that is not allowed.......
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.